Exenatide Treatment Exerts Anxiolytic- and Antidepressant-Like Effects and Reverses Neuropathy in a Mouse Model of Type-2 Diabetes
[ X ]
Tarih
2014
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Int Scientific Information, Inc
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Background: Comorbid neurobehavioral disturbances and type-2 diabetes mellitus (T2DM) warrant immediate research attention. Exenatide, which is a potent and selective agonist for the glucagon-like peptide-1 (GLP-1), is used in the treatment of T2DM. Exenatide displays a multitude of effects in the central nervous system. The aim of this study was to investigate the anxiolytic- and antidepressant-like effects and analgesic effects of exenatide in a type-2 diabetic mouse model. Material/Methods: Modified elevated plus-maze test for anxiolytic- like, forced swimming test for depression-like behavior and hotplate test for neuropathy were used as behavioral tasks. Behavioral parameters were investigated in a streptozocin - (100 mg/kg, i.p.) and nicotinamide - (240 mg/kg, i.p.) induced type-2 diabetic mouse model. Exenatide (0.1 mu g/kg, s.c., twice daily) was administered for 2 weeks. Vehicle (control), diabetic, and exenatide-treated diabetic mice were tested. Results: Our results confirm that exenatide exerts anxiolytic- and antidepressant-like effects and might be effective in diabetic neuropathy in a diabetic mouse model. Conclusions: Exenatide may be a good candidate as a treatment option for depression, anxiety, and neuropathy in patients with type-2 diabetes.
Açıklama
Anahtar Kelimeler
Anti-Anxiety Agents, Behavior, Animal, Depression, Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1
Kaynak
Medical Science Monitor Basic Research
WoS Q Değeri
N/A
Scopus Q Değeri
Cilt
20
